STOCK TITAN

VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in the ‘Updates in Neuropsych’ panel at the virtual William Blair Biotech Focus Conference 2021 on July 15, 2021 at 9:00 a.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference.

William Blair Biotech Focus Conference 2021  

Panel:Updates in Neuropsych
Date:Thursday, July 15 at 9:00 a.m. PT
Webcast:https://wsw.com/webcast/blair59/panel8/2166208
Registration:To attend the virtual conference, please contact your William Blair representative.

The panel will be held virtually, and a live webcast will be accessible through the News/Events page of the Investors section of the company’s website at www.VistaGen.com.

About VistaGen
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on TwitterLinkedIn, and Facebook.

Company Contacts
Mark A. McPartland / Mark Flather
VistaGen Therapeutics, Inc.
Phone: +1 (650) 577-3606/+1 (650) 577-3617
Email: IR@vistagen.com


VistaGen Therapeutics, Inc.

NASDAQ:VTGN

VTGN Rankings

VTGN Latest News

VTGN Stock Data

130.53M
15.25M
0.17%
63.16%
4.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About VTGN

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.